HLL Biotech Ltd.(HBL) is partnering with Ministry of Health and Family Welfare, Government of India to set up a premium facility for production of vaccines for the National Immunization Programme and other new generation vaccines. HBL has been established at Chengalpattu near Chennai (Tamil Nadu) in Southern India. The main objective of HBL is to ensure safe and effective vaccines at affordable prices.
With the Rs 5940 million project, spread over 100 acres, HBL aims to promote the vaccine security of India.
HBL, with an annual capacity of 585 million doses, will manufacture Pentavalent combination (DPT plus Hep B plus Hib), BCG, Measles, Hepatitis B, Human Rabies, Hib and Japanese Encephalitis (JE) vaccines in the first phase. HBL also seeks to develop a strong R&D base for development of futuristic vaccines, apart from manufacturing and supplying vaccines required for the Universal Immunization Programme (UIP) of India.
HBL is a project of national importance which will ensure the uninterrupted supply of vaccines for the UIP at affordable prices.
The state-of-the-art WHO-pre-qualified facility, the first of its kind in the public sector, will also have the capacity to manufacture vaccines for Meningococcal, Rotaviral, Dengue and Pneumococcal diseases in its multi-bacterial and multi-viral facilities to meet any epidemic or pandemic situations.